Business Context and Reporting Period
ORIC Pharmaceuticals, Inc. filed a Form 8-K dated November 8, 2021, under Items 2.02 and 9.01(d). The filing announces the company’s financial results for the fiscal quarter ended September 30, 2021 and attaches a related press release as Exhibit 99.1.
Financial Results and Key Metrics
The filing text provided does not include the financial results, revenue, net loss, cash flow, margins, debt, liquidity, or other operating metrics. Those details appear to be contained in Exhibit 99.1, but the exhibit content is not included in the provided filing text.
Changes Versus Prior Comparable Period
The provided filing text does not describe material changes versus the prior-year or prior-quarter comparable period.
Guidance, Outlook, Risks, and Unusual Items
No guidance, outlook, management commentary, risk updates, contingencies, or unusual items are presented in the provided text. The filing states that the information furnished under Items 2.02 and 9.01, including Exhibit 99.1, is not deemed filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly specified.
Important Facts to Verify
- Obtain and review Exhibit 99.1 for the quarter’s revenue, operating expenses, net loss, cash position, cash runway, and cash-flow metrics.
- Verify any management guidance or clinical-development updates included in the press release.
- Compare the reported results with the prior comparable period and assess changes in liquidity and expected funding needs.
- Confirm whether the press release identifies material clinical, regulatory, financing, or other contingencies.